Close Menu

NEW YORK – Biolidics said today that its ClearCell FX1 System has obtained a Class I registration from the China National Medical Products Administration.

ClearCell FX1 is a liquid biopsy platform that separates and enriches cancer cells from a blood sample for either quantitation or further analyses like molecular and genomic profiling.

With the NMPA approval, Biolidics can now directly market and sell the platform to hospitals, laboratories, research institutions, and other medical institutions for use in in vitro diagnostic testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.